Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: CSL Limited

Market Cap 3.68TCr 3.18TCr 2.93TCr 2.74TCr 5.14TCr 3,49800Cr 5.22TCr 35TCr 13TCr 1,70300Cr 14TCr 14TCr 5,89500Cr P/E Ratio 2026 *
-48.7x
P/E Ratio 2027 * 24.5x
Enterprise Value 4.56TCr 3.94TCr 3.63TCr 3.4TCr 6.37TCr 4,33800Cr 6.47TCr 43TCr 17TCr 2,11100Cr 17TCr 17TCr 7,31100Cr EV / Sales 2026 *
2.97x
EV / Sales 2027 * 2.86x
Free-Float
99.3%
Yield 2026 *
3.76%
Yield 2027 * 3.87%
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Tech/Sci/R&D Officer 64 01/10/2020
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 14/08/2013
Director/Board Member 68 16/02/2016
Change 5-day change 1-year change 3-year change Capi.($)
+0.11%-3.67%+15.66%-20.23% 6.23TCr
+1.44%+5.33%+68.19%+222.27% 6.06TCr
+0.70%+29.50%+29.50%+29.50% 3.95TCr
+0.05%+2.41%+53.12%-34.32% 2.95TCr
+0.65%+6.01%+60.19%+75.19% 2.17TCr
+0.54%+5.21%+87.14%-61.00% 1.98TCr
+4.80%-0.20%-5.27%+115.05% 1.7TCr
+0.18%-1.66%+54.11%+100.91% 1.62TCr
+0.55%+9.84%+145.12%+240.77% 1.31TCr
Average +1.00%+3.11%+56.42%+74.24% 3.11TCr
Weighted average by Cap. +0.86%+2.41%+48.50%+69.82%

Financials

2026 *2027 *
Net sales 1.54TCr 1.33TCr 1.22TCr 1.15TCr 2.15TCr 1,46200Cr 2.18TCr 14TCr 5.64TCr 71TCr 5.77TCr 5.65TCr 2,46400Cr 1.57TCr 1.35TCr 1.25TCr 1.17TCr 2.19TCr 1,49100Cr 2.22TCr 15TCr 5.75TCr 73TCr 5.89TCr 5.76TCr 2,51300Cr
Net income -89Cr -77Cr -71Cr -67Cr -124.91Cr -8.5TCr -126.85Cr -840.81Cr -327.82Cr -4.14TCr -335.78Cr -328.63Cr -14TCr 122.45Cr 105.76Cr 97Cr 91Cr 170.96Cr 12TCr 173.6Cr 1.15TCr 448.65Cr 5.66TCr 459.54Cr 449.75Cr 20TCr
Net Debt 883.59Cr 763.16Cr 703.25Cr 658.28Cr 1.23TCr 84TCr 1.25TCr 8.3TCr 3.24TCr 41TCr 3.32TCr 3.25TCr 1,41500Cr 808.42Cr 698.23Cr 643.42Cr 602.27Cr 1.13TCr 77TCr 1.15TCr 7.6TCr 2.96TCr 37TCr 3.03TCr 2.97TCr 1,29500Cr
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!